Biogen, Inc.'s decade-long Aduhelm (aducanumab) story line took many twists and turns over the course of its development, capturing national attention in 2021 when the drug became the first anti-amyloid antibody to reach the US market for Alzheimer's disease on scant efficacy evidence and quickly fading from the spotlight when the hyped commercial launch failed and a second anti-amyloid drug fromEisai Co., Ltd. and Biogen, Leqembi (lecanemab), gained full approval from the US Food and Drug Administration in 2023.
Key Takeaways
- Biogen will discontinue the development and commercialization of Aduhelm, including the ongoing Phase IV confirmatory trial ENVISION.
- Biogen took a $60m charge in the fourth quarter to close out the costs of the Aduhelm program, a small cost compared to the steep bill Biogen has already put toward the development and commercialization
Now, without any fanfare and as many industry watchers and investors expected, Biogen announced on 31 January that it will discontinue the development and commercialization of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
